Literature DB >> 11085545

Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro.

A Collen1, S M Smorenburg, E Peters, F Lupu, P Koolwijk, C Van Noorden, V W van Hinsbergh.   

Abstract

Cancer patients treated for venous thromboembolism with low molecular weight heparin (LMWH) have a better survival rate than patients treated with unfractionated heparin (UFH). Because fibrin-associated angiogenesis is an important determinant in the progression and metastasis of many solid tumors, the effects of heparins on in vitro angiogenesis were investigated. Both UFH and LMWH inhibited bFGF-induced proliferation of human microvascular endothelial cells (hMVECs) to the same the extent (36-60%). VEGF165-induced proliferation was inhibited to a to a lesser extent (19-33%). Turbidity measurements and electron microscopy showed that the presence of LMWH during polymerization of the fibrin matrix led to a more transparent rigid network with thin fibrin bundles, whereas the presence of UFH resulted in a more opaque more porous network with thick fibrin fibers. We used a human in vitro angiogenesis model, which consisted of hMVECs seeded on top of a fibrin matrix, and stimulated the cells with basic fibroblast growth factor plus tumor necrosis factor a to induce capillary-like tubular structures. The formation of capillary-like tubular structures was retarded with matrices polymerized in the presence of LMWH (46% inhibition compared with a control matrix for both 1.5 and 10 units/ml LMWH), whereas matrices polymerized in the presence of UFH facilitated tubular structure formation (72 and 36% stimulation compared with a control matrix for 1.5 and 10 units/ml UFH, respectively). Similar results were obtained for cells stimulated with vascular endothelial growth factor plus tumor necrosis factor alpha. These data demonstrate the inhibitory effect of heparins on proliferation of hMVECs and provide a novel mechanism by which LMWH may affect tumor progression, namely reduced ingrowth of microvascular structures in a fibrinous stroma matrix by rendering it less permissive for invasion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085545

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy.

Authors:  Duy T Dao; Lorenzo Anez-Bustillos; Jared Ourieff; Amy Pan; Paul D Mitchell; Hiroko Kishikawa; Gillian L Fell; Meredith A Baker; Randolph S Watnick; Hong Chen; Thomas E Hamilton; Michael S Rogers; Diane R Bielenberg; Mark Puder
Journal:  Angiogenesis       Date:  2018-06-28       Impact factor: 9.596

Review 2.  Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms.

Authors:  Ning Zhang; Weihua Lou; Fang Ji; Lihua Qiu; Benjamin K Tsang; Wen Di
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-24       Impact factor: 4.553

3.  A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.

Authors:  Xu Wang; Jun Li; Yuxiang Wang; Lydia Koenig; Ada Gjyrezi; Paraskevi Giannakakou; Edwin H Shin; Mourad Tighiouart; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-07-11       Impact factor: 15.881

4.  Protease-activated receptors in cancer: A systematic review.

Authors:  Na Han; Ketao Jin; Kuifeng He; Jiang Cao; Lisong Teng
Journal:  Oncol Lett       Date:  2011-04-08       Impact factor: 2.967

5.  Improvement in Blood Supply After "Heparin-Dextran" Therapy in Patients of Buerger's Disease with Critical Limb Ischemia.

Authors:  Sanand Bag; Arunanshu Behera; Niranjan Khandelwal; J R Bapuraj; Rakesh Kumar Vasishta
Journal:  Indian J Surg       Date:  2012-06-19       Impact factor: 0.656

6.  Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells.

Authors:  Dong Yun Lee; Sung Won Lee; Sang Kyoon Kim; Myungjin Lee; Hyo Won Chang; Hyun Tae Moon; Youngro Byun; Sang Yoon Kim
Journal:  Pharm Res       Date:  2009-10-15       Impact factor: 4.200

7.  The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.

Authors:  I Debergh; N Van Damme; P Pattyn; M Peeters; W P Ceelen
Journal:  Br J Cancer       Date:  2010-02-02       Impact factor: 7.640

8.  Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate.

Authors:  Koji M Nishiguchi; Keiko Kataoka; Shu Kachi; Keiichi Komeima; Hiroko Terasaki
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

9.  The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

Authors:  Jong Chul Park; Caroline F Pratz; Anteneh Tesfaye; Robert A Brodsky; Emmanuel S Antonarakis
Journal:  Clin Genitourin Cancer       Date:  2014-06-11       Impact factor: 2.872

Review 10.  Polyphosphate and omptins: novel bacterial procoagulant agents.

Authors:  Thomas H Yun; James H Morrissey
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.